Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (416)	9/30/2002 9:21:51 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1022

"If you're trying to produce anything anti-human, there are very simple serology lessons that scream "avoid MEDX and ABGX". " Rick, please can you be bit more specific, in plain language? It is true that so far CATG have more candidates (seven) in clinic than ABGX (five). CATG is older company than ABGX ('96 versus '98) with 100 billions antibodies in library. Many predicted that time to move hmAb candidate trough preclinical development phase will be much shorter than for small molecules (1-2 years versus 3-5 years). Seems that it is not a case. What you see as main problem(s)? Miljenko

To: scaram(o)uche who wrote (416)	10/2/2002 11:09:44 AM
From: nigel bates	Read Replies (2) \| Respond to of 1022

why aren't more antibodies described, from academic collaborators, in the literature? XenoMouse or HuMab, a search comes up with few recent successes. And those involve bacteria, bacterial toxins, and HIV... I don't have an answer to the question - not that it doesn't worry me... I do have a lot more CAT than ABGX. As regards getting MABs into the clinic, is it possible that the current environment is making companies overcautious about committing to trials ? Interesting snippet from today's CRGN PR, though - "...101 antibody projects, from which 28 fully human monoclonal antibodies are being evaluated in conjunction with Abgenix as potential therapeutics..." Back in May - "...The development of PDGF D mAbs is an important example of one of the 17 mAbs we are currently evaluating with Abgenix..."